ChromaDex Loss Down, Tru Niagen Sales Up 22%
Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.
You may also be interested in...
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.
In vitro data shows potential for Chromadex' Tru Niagen dietary supplement to block coronavirus infection. Chromadex' CEO Rob Fried tells HBW Insight about the company's background and Tru Niagen's recent UK launch.
In response to what it says was unexpected airing of ChromaDex' ongoing disputes with Elysium Health, CRN will require speakers at its events to submit materials its review. Chromadex says CRN asked for the type of presentation its chairman made while Elysium Health wasn’t surprised a ChromaDex executive would comment on the litigation.